Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases
AssigneePTC Therapeutics, Inc.
InventorsRichard Wilde, Ellen Welch, Gary M. Karp
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.
Claims59
A method of treating or preventing a disease resulting from a somatic mutation comprising administering to a patient in need thereof an effective amount of a compound of Formula 1:
- wherein:
- Y and Z are independently selected from N or C;
- W is N or CH;
- n is 0, 1, 2 or 3;
- R1 is hydrogen, a C6 to C8 aryl which is optionally substituted with a carboxy group, or R1 is absent when Z is N;
- R2 is hydrogen;
- a C6 to C8 aryl which is optionally substituted with one, two, or three independently selected Ra groups;
- a four to seven membered heterocycle which is optionally substituted with one or more independently selected C1-C6 alkyl groups or a three to seven membered heterocycle;
- or R2 is absent when Y is N;
- R is independently selected from a halogen;
- a carboxy group;
- a C1-C6 alkyl group optionally substituted with a four to six membered heterocycle, a C6-C8 aryloxy group, or an amino group, wherein the four to six membered heterocycle, C6-C8 aryloxy group, and amino group are optionally substituted with one or two independently selected C1-C6 alkyl or C6-C8 aryl groups which C6-C8 aryl groups are optionally and independently substituted with one or more C1-C6 alkyl groups;
- a C1-C6 alkoxy;
- a C6-C8 aryloxy;
- a C6-C8 aryl optionally substituted with one or more independently selected halogen, C1-C4 alkyl, C1-C4 haloalkyl, oxy, C1-C4 alkoxy, or C1-C4 haloalkoxy groups;
- an amino group optionally substituted with one or two independently selected C6-C8 aryl or C1-C6 alkyl groups, which are optionally substituted with a hydroxy, a C6-C8 aryl, or a nine to ten membered heterocycle having two ring structures;
- a carbonyl group substituted with a five to six membered heterocycle group;
- a four to seven membered heterocycle group optionally substituted with one more C1-C4 alkyl or oxo groups;
- a nine to ten membered heterocycle having two ring structures;
- or two R groups, wherein R may also include an oxy group, together with the hetero-bicycle to which they are attached form a twelve to thirteen membered heterocycle having three ring structures;
- wherein Ra is a halogen;
- a C1-C6 alkyl;
- a C1-C6 alkoxy which is optionally substituted with one or more independently selected halogen groups;
- a C6-C8 aryl;
- a four to six-membered heterocycle which is optionally substituted with one or more independently selected oxo groups;
- a carbonyl which is optionally substituted with a hydroxy or a C1-C6 alkoxy group;
- a carbamoyl;
- an amino which is optionally substituted with an independently selected C1-C6 alkyl group, wherein the C1-C6 alkyl group is optionally substituted with one or more independently selected halogens or hydroxyl groups;
- or two Ra groups, wherein Ra may also include an oxy group, together with the C6-C8 aryl group to which they are attached form a nine to ten membered heterocycle having two ring structures, wherein the nine to ten membered heterocycle having two ring structures is optionally substituted with one or more independently selected halogens;
- or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph of said compound of Formula 1.
A method of treating or preventing a disease resulting from a somatic mutation comprising administering to a patient in need thereof an effective amount of a compound of Formula 2:
- wherein:
- Y and Z are independently selected from N or C;
- W is N or CH;
- n is 0, 1, 2 or 3;
- R1 is hydrogen, a C6 to C8 aryl which is optionally substituted with a carboxy group, or R1 is absent when Z is N;
- R2 is hydrogen;
- a C6 to C8 aryl which is optionally substituted with one, two, or three independently selected Ra groups;
- a four to seven membered heterocycle which is optionally substituted with one or more independently selected C1-C6 alkyl groups or a three to seven membered heterocycle;
- or R2 is absent when Y is N;
- R is independently selected from a halogen;
- a carboxy group;
- a C1-C6 alkyl group optionally substituted with a four to six membered heterocycle, a C6-C8 aryloxy group, or an amino group, wherein the four to six membered heterocycle, C6-C8 aryloxy group, and amino group are optionally substituted with one or two independently selected C1-C6 alkyl or C6-C8 aryl groups which C6-C8 aryl groups are optionally and independently substituted with one or more C1-C6 alkyl groups;
- a C1-C6 alkoxy;
- a C6-C8 aryloxy;
- a C6-C8 aryl optionally substituted with one or more independently selected halogen, C1-C4 alkyl, C1-C4 haloalkyl, oxy, C1-C4 alkoxy, or C1-C4 haloalkoxy groups;
- an amino group optionally substituted with one or two independently selected C6-C8 aryl or C1-C6 alkyl groups, which are optionally substituted with a hydroxy, a C6-C8 aryl, or a nine to ten membered heterocycle having two ring structures;
- a carbonyl group substituted with a five to six membered heterocycle group;
- a four to seven membered heterocycle group optionally substituted with one more C1-C4 alkyl or oxo groups;
- a nine to ten membered heterocycle having two ring structures;
- or two R groups, wherein R may also include an oxy group, together with the hetero-bicycle to which they are attached form a twelve to thirteen membered heterocycle having three ring structures;
- wherein Ra is a hydroxy group;
- a halogen;
- a C1-C6 alkyl which is optionally substituted with one or more independently selected halogen or hydroxy groups;
- a C1-C6 alkoxy which is optionally substituted with one or more independently selected halogen or phenyl groups;
- a C4-C8 cycloalkyl which is optionally substituted with one or more independently selected C1-C4 alkyl groups;
- an —Rb group;
- a —O—Rb group;
- a four to six-membered heterocycle which is optionally substituted with one or more independently selected C1-C4 alkyl, oxo, or —Rb groups;
- a nine to ten membered heterocycle having two ring structures;
- a carbonyl which is optionally substituted with a hydroxy, a C1-C4 alkyl, or a C1-C4 alkoxy group;
- a carbamoyl which is optionally substituted with one or two independently selected C1-C4 alkyl groups;
- a nitro group;
- a cyano group;
- a thio which is optionally substituted with a hydroxy, a C1-C4 alkyl, or —Rb group;
- a sulfonyl which is optionally substituted with a hydroxy, a C1-C4 alkyl, or —Rb group;
- an amino which is optionally substituted with one or two independently selected C1-C6 alkyl, sulfonyl, or carbonyl groups;
- wherein the C1-C4 alkyl group is optionally substituted with one or more independently selected halogens or hydroxyl groups, wherein the aminosulfonyl group is optionally substituted with a hydroxy, a C1-C4 alkyl, or —Rb group, and wherein the aminocarbonyl group is optionally substituted with a C1-C4 alkyl, a C1-C4 haloalkyl, a benzoxy, or an amino group which is optionally substituted with an —Rb group;
- or two Ra groups, wherein Ra may also include an oxy group, together with the C6-C8 aryl group to which they are attached form a nine to ten membered heterocycle having two ring structures, wherein the nine to ten membered heterocycle having two ring structures is optionally substituted with one or more independently selected halogens;
- wherein —Rb is a C6-C8 aryl which is optionally substituted with one or more groups independently selected from the following:
- a hydroxy, a halogen, a C1-C4 alkyl group, a C1-C4 haloalkyl group, a C1-C4 alkoxy group, and an amino group which is optionally substituted with one or two independently selected C1-C4 alkyl groups;
- or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph of said compound of Formula 2.
A method of treating or preventing a disease resulting from a somatic mutation comprising administering to a patient in need thereof an effective amount of a compound of Formula 3:
- wherein:
- Y and Z are independently selected from N or C;
- W is N or CH;
- n is 0, 1, 2 or 3;
- R1 is absent or a C6 to C8 aryl which is optionally substituted with a carboxy group;
- R2 is absent;
- a C6 to C8 aryl which is optionally substituted with one, two, or three independently selected Ra groups;
- or a four to seven membered heterocycle which is optionally substituted with one or more C1-C4 alkyl groups, or a four to six membered heterocycle;
- R is independently selected from a halogen;
- a carboxy group;
- a C1-C6 alkyl group optionally substituted with a C6-C8 aryloxy group, an imidazole group, or an amino group which is optionally substituted with one or two independently selected C1-C6 alkyl or C6-C8 aryl groups;
- a C1-C6 alkoxy;
- a C6-C8 aryloxy;
- a C6-C8 aryl optionally substituted with one or more halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, or C1-C4 haloalkoxy groups;
- an amino group optionally substituted with one or two independently selected C6-C8 aryl or C1-C6 alkyl groups, which are optionally substituted with a hydroxy, a phenyl, or a benzo[1,3]dioxole group;
- a carbonyl group optionally substituted with a five to six membered heterocycle group;
- a four to seven membered heterocycle group optionally substituted with one more C1-C4 alkyl or oxo groups;
- a nine to ten membered heterocycle having two ring structures;
- or two R groups together with the hetero-bicycle to which they are attached form a twelve to thirteen membered heterocycle having three ring structures;
- wherein Ra is a hydroxy group;
- a halogen;
- a C1-C4 alkyl which is optionally substituted with one or more independently selected halogen or hydroxy groups;
- a C1-C4 alkoxy which is optionally substituted with one or more independently selected halogen or phenyl groups;
- a C4-C8 cycloalkyl which is optionally substituted with one or more independently selected C1-C4 alkyl groups;
- an —Rb group;
- a —O—Rb group;
- a four to six-membered heterocycle which is optionally substituted with one or more independently selected C1-C4 alkyl, oxo, or —Rb groups;
- a nine to ten membered heterocycle having two ring structures;
- a carbonyl which is optionally substituted with a hydroxy, a C1-C4 alkyl, or a C1-C4 alkoxy group;
- a carbamoyl which is optionally substituted with one or two C1-C4 alkyl groups;
- a nitro group;
- a cyano group;
- a thio which is optionally substituted with a hydroxy, a C1-C4 alkyl, or —Rb group;
- a sulfonyl which is optionally substituted with a hydroxy, a C1-C4 alkyl, or —Rb group;
- an amino which is optionally substituted with one or two independently selected C1-C4 alkyl, sulfonyl, or carbonyl groups;
- wherein the aminosulfonyl group is optionally substituted with a hydroxy, a C1-C4 alkyl, or —Rb group;
- and wherein the aminocarbonyl group is optionally substituted with a C1-C4 alkyl, a C1-C4 haloalkyl, a benzoxy, or an amino group which is optionally substituted with an —Rb group, or two Ra groups together with the phenyl ring to which they are attached form a benzo[1,3]dioxole optionally substituted with one or more halogens or a 2,3-dihydro-benzofuran group;
- wherein —Rb is a C6-C8 aryl which is optionally substituted with one or more of the following:
- a hydroxy, a halogen, a C1-C4 alkyl group, a C1-C4 haloalkyl group, a C1-C4 alkoxy group, or an amino group which is optionally substituted with one or more C1-C4 alkyl groups;
- or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph of said compound of Formula 3.
A method of treating or preventing a disease resulting from a somatic mutation comprising administering to a patient in need thereof an effective amount of a compound of Formula 4:
- wherein:
- Y and Z are independently selected from N or C;
- W is N or CH;
- R1 is hydrogen, a C6 to C8 aryl which is optionally substituted with a carboxy group, or R1 is absent when Z is N;
- R2 is hydrogen;
- a C6 to C8 aryl which is optionally substituted with one, two, or three independently selected Ra groups;
- a four to seven membered heterocycle which is optionally substituted with one or more independently selected C1-C6 alkyl groups or a three to seven membered heterocycle;
- or R2 is absent when Y is N;
- R3 is hydrogen;
- a halogen;
- a carboxy group;
- or R3, wherein R3 may also include an oxy group, together with R4 and the heterocycle to which they are attached preferably form a twelve to thirteen membered heterocycle with three ring structures;
- R4 is hydrogen, a halogen;
- a carboxy group;
- a C1-C6 alkyl group;
- a C1-C6 alkoxy;
- a C6-C8 aryloxy;
- a C6-C8 aryl optionally substituted with one or more independently selected halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, or C1-C4 haloalkoxy groups;
- an amino group optionally substituted with one or two independently selected C6-C8 aryl or C1-C6 alkyl groups, which are optionally substituted with a hydroxy, a phenyl, or a benzo[1,3]dioxole group;
- a carbonyl group substituted with a five to six membered heterocycle group;
- or a four to seven membered heterocycle group optionally substituted with one more C1-C4 alkyl or oxo groups;
- a nine to ten membered heterocycle having two ring structures;
- or R3 together with R4 and the heterocycle to which they are attached preferably form a twelve to thirteen membered heterocycle with three ring structures;
- R5 is independently selected from:
- hydrogen, a halogen;
- a carboxy group;
- a C1-C6 alkyl group optionally substituted with a C6-C8 aryloxy group, an imidazole group, or an amino group which is optionally substituted with one or two independently selected C1-C6 alkyl or C6-C8 aryl groups;
- a C1-C6 alkoxy;
- a C6-C8 aryloxy;
- a C6-C8 aryl optionally substituted with one or more independently selected halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, or C1-C4 haloalkoxy groups;
- a carbonyl group substituted with a five to six membered heterocycle group;
- a four to seven membered heterocycle group optionally substituted with one more C1-C4 alkyl or oxo groups;
- or a nine to ten membered heterocycle having two ring structures;
- or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph of said compound of Formula 4.
A method of treating or preventing an autoimmune disease, a blood disease, a collagen disease, diabetes, a neurodegenerative disease, a cardiovascular disease, a pulmonary disease, or an inflammatory disease or central nervous system disease comprising administering to a patient in need thereof an effective amount of a compound of Formula 1, 2, 3, or 4, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph thereof.
A method of treating or preventing familial polycythemia, immunodeficiency, kidney disease, muscular dystrophy, heart disease, kidney stones, ataxia-telangiectasia, cystic fibrosis, familial hypercholesterolemia, retinitis pigmentosa, amyloidosis, hemophilia, Alzheimer's disease, Tay Sachs disease, Niemann Pick disease, Parkinson's disease, atherosclerosis, giantism, dwarfism, hyperthyroidism, aging, obesity, Duchenne muscular dystrophy, epidermolysis bullosa or Marfan syndrome comprising administering to a patient in need thereof an effective amount of a compound of Formula 1, 2, 3, or 4, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph thereof.
A method of treating or preventing cancer in a human comprising administering to a human in need thereof an effective amount of a compound of Formula 1, 2, 3, or 4, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph thereof.
A method of treating or preventing a disease associated with a mutation of the p53 gene comprising administering to a patient in need thereof an effective amount of a compound of Formula 1, 2, 3, or 4 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph thereof.
A method of inhibiting the growth of a cancer cell comprising contacting the cancer cell with an effective amount of a compound of Formula 1, 2, 3, or 4 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph thereof.
A method for selectively producing a protein in a mammal comprising transcribing a gene containing a nonsense mutation in the mammal;
- and providing an effective amount of a compound of the present invention to said mammal, wherein said protein is produced by said mammal.
A method of treating or preventing a disease resulting from a somatic mutation comprising administering to a patient in need thereof an effective amount of one or more compounds from Compounds 1 through 142.
A method of treating or preventing a disease resulting from a somatic mutation comprising administering to a patient in need thereof an effective amount of one or more compounds from Compounds 19, 20, 42, 49, 53, 56, 58, 59, 85, 91, 94, 96, 100, 101, and 102.
A compound of Formula 1
- wherein:
- Y and Z are independently selected from N or C;
- W is N or CH;
- n is 0, 1, 2 or 3;
- R1 is hydrogen, a C6 to C8 aryl which is optionally substituted with a carboxy group, or R1 is absent when Z is N;
- R2 is hydrogen;
- a C6 to C8 aryl which is optionally substituted with one, two, or three independently selected Ra groups;
- a four to seven membered heterocycle which is optionally substituted with one or more independently selected C1-C6 alkyl groups or a three to seven membered heterocycle;
- or R2 is absent when Y is N;
- R is independently selected from a halogen;
- a carboxy group;
- a C1-C6 alkyl group optionally substituted with a four to seven membered heterocycle, a C6-C8 aryloxy group, or an amino group, wherein the four to seven membered heterocycle, C6-C8 aryloxy group, and amino group are optionally substituted with one or two independently selected C1-C6 alkyl or C6-C8 aryl groups which C6-C8 aryl groups are optionally and independently substituted with one or more C1-C6 alkyl groups;
- a C1-C6 alkoxy;
- a C6-C8 aryloxy;
- a C6-C8 aryl optionally substituted with one or more independently selected halogen, C1-C4 alkyl, C1-C4 haloalkyl, oxy, C1-C4 alkoxy, or C1-C4 haloalkoxy groups;
- an amino group optionally substituted with one or two independently selected C6-C8 aryl or C1-C6 alkyl groups, which are optionally substituted with a hydroxy, a C6-C8 aryl, or a nine to ten membered heterocycle having two ring structures;
- a carbonyl group optionally substituted with a five to six membered heterocycle group;
- a four to seven membered heterocycle group optionally substituted with one more C1-C4 alkyl or oxo groups;
- a nine to ten membered heterocycle having two ring structures;
- or two R groups, wherein R may also include an oxy group, together with the hetero-bicycle to which they are attached form a twelve to thirteen membered heterocycle having three ring structures;
- wherein Ra is a halogen;
- a C1-C6 alkyl;
- a C1-C6 alkoxy which is optionally substituted with one or more independently selected halogen groups;
- a C6-C8 aryl;
- a four to seven membered heterocycle which is optionally substituted with one or more independently selected oxo groups;
- a carbonyl which is substituted with a hydroxy or a C1-C6 alkoxy group;
- a carbamoyl;
- an amino which is optionally substituted with an independently selected C1-C6 alkyl group, wherein the C1-C6 alkyl group is optionally substituted with one or more independently selected halogens or hydroxyl groups;
- or two Ra groups, wherein Ra may also include an oxy group, together with the C6-C8 aryl group to which they are attached form a nine to ten membered heterocycle having two ring structures, wherein the nine to ten membered heterocycle having two ring structures is optionally substituted with one or more independently selected halogens;
- or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph of said compound of Formula 1.
A compound having the formula (Compound NO:
- 1):
Dependencies are inferred from the claim text.